Status:
COMPLETED
Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2
Lead Sponsor:
Azienda USL Reggio Emilia - IRCCS
Conditions:
Precancerous Conditions
Neoplasms
Eligibility:
FEMALE
25-59 years
Phase:
NA
Brief Summary
In industrialized countries, cervical cancer is a well controlled disease thanks to the diffusion of Pap test and, in particular, to organized screening programs, which are able to detect and treat pr...
Detailed Description
Individual data about the following study steps are collected according a fixed format: 1. recruited women 2. HPV DNA result 3. cytology and randomization results 4. p16 result 5. mRNA result 6. colp...
Eligibility Criteria
Inclusion
- women invited for a new screening round based on HPV DNA test
Exclusion
- women not resident in the screening area, or pregnant, or with treated CIN in the 5 previous years, or in post-colposcopy follow up, or in repetition for unsatisfactory cytology.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
41127 Patients enrolled
Trial Details
Trial ID
NCT01837693
Start Date
June 1 2013
End Date
January 1 2017
Last Update
June 26 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Unità Locale Socio-Sanitaria 17 Este Monselice
Este, Italy
2
Istituto per lo Studio e la Prevenzione Oncologica
Florence, Italy
3
Azienda Sanitaria Locale 2- Regione Umbria
Perugia, Italy
4
Azienda Sanitaria della Provincia Autonoma di Trento
Trento, Italy